The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Open accessAbstract
DNA and RNA stimulate the mammalian innate immune system through activation of Toll-like receptors (TLRs). DNA containing methylated CpG motifs, however, is not stimulatory. Selected nucleosides in naturally occurring RNA are also methylated or otherwise modified, but the immunomodulatory effects of these alterations remain untested. We show that RNA signals through human TLR3, TLR7, and TLR8, but incorporation of modified nucleosides m5C, m6A, m5U, s2U, or pseudouridine ablates activity. Dendritic cells (DCs) exposed to such modified RNA express significantly less cytokines and activation markers than those treated with unmodified RNA. DCs and TLR-expressing cells are potently activated by bacterial and mitochondrial RNA, but not by mammalian total RNA, which is abundant in modified nucleosides. We conclude that nucleoside modifications suppress the potential of RNA to activate DCs. The innate immune system may therefore detect RNA lacking nucleoside modification as a means of selectively responding to bacteria or necrotic tissue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which is widely believed to be critical to the recent success of mRNA vaccines1,2,10,37,38”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [37]
In the citing paper
“Modifications to the spike protein are intended to reduce the innate immune response by inhibiting proinflammatory cytokines, while at the same time, the lipid nanoparticle vehicle/EV for the mRNA acts as an adjuvant to enhance the immune response. 194-196”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [194]
In the citing paper
“In general, in vitro transcribed mRNA has the risk of triggering various pattern recognition receptors in the endosome (e.g., TLR7/8) or the cytoplasm (e.g., RIG-I), which lead to an anti-viral response, followed by a shutdown of translation that can lower expression of the mRNA-encoded protein.25”
From Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines (2017) · cites this paper as [25]
In the citing paper
“Transferring this concept to in vitro transcribed mRNA, for instance, pseudouridine-containing mRNAs reduced activation of known RNA sensors substantially.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [20]
In the citing paper
“Obviously, cytokine secretion by RNA-transfected cells strongly correlated with the extent of nucleoside modifications.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [20]
In the citing paper
“In addition, nucleoside modifications are well known to limit or even inhibit RNA sensor engagement.20,21,22”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [20]
In the citing paper
“Others strategies aim to impair the PRR recognition of IVT mRNA with the use of modified nucleosides,16 uridine depletion in the coding sequence,17 or dephosphorylation of 5′PPP mRNAs.18”
From Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA (2021) · cites this paper as [16]
In the citing paper
“In particular, we focused on ψ and m1ψ, since these substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors (TLR7 and TLR8)68, RIG‑I, and PKR69–71.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [70]
In the citing paper
“Studies have found that replacing original nucleosides with m6A and s2U inhibits activation of TLR3, whereas activation of TLR7 and TLR8 is blocked when using ψ, 5-methyluridine (m5U), m6A, and s2U, thereby inhibiting the innate immune responses and improving protein translation efficiency.81,159,171”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [81]
In the citing paper
“Nucleoside-modified mRNA can reduce the activation of TLRs, retinoic acid-inducible gene I (RIG-I), protein kinase R (PKR), and 2′-5′-oligoadenylate synthetase (OAS). Additionally, nucleoside modification increases translation activity and resistance against RNase L-mediated degradation.54,81,173–176”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [81]
In the citing paper
“To avoid this, Karikó and colleagues found that adding modified nucleosides during IVT of mRNA can significantly reduce the host inflammatory response without affecting protein expression.81,159”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [81]
In the citing paper
“However, the incorporation of modified nucleosides into mRNA can significantly improve the biological stability and translational capacity of the mRNA while decreasing the innate immune response.36, 37, 38”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [36]
In the citing paper
“not only viral RNA, but also endogenous mRNA associated with apoptotic cells as well as in vitro transcribed (IVT) mRNA could bind and activate TLR3, TLR7 and TLR8 [4,5]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [5]
In the citing paper
“the many modifications observed in natural mRNA are in fact a way to avoid immune recognition, allowing the immune system to distinguish self from non-self RNA [5]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [5]
In the citing paper
“Chemical modifications of specific IVT mRNA nucleotides, such as pseudouridine (ψ) and N1-methylpseudouridine (m1ψ), can reduce innate immune sensing of exogenous mRNA translation2,4,7,182.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [182]
In the citing paper
“In 2004, Karikó and colleagues observed, while exposing ex vivo human DCs to mRNA from different sources, that these cells tolerated mammalian mRNA, while strong inflammatory cytokine responses were detected upon the delivery of mRNA derived from bacteria, necrotic mammalian cells and IVT mRNA [39,40].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [39]
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 3×
“To determine whether m5C and m6A evidence, first that bacterial RNA transfected to 293-exert a dominant stimulatory effect, transcripts with hTLR9 did not induce IL-8 secretion (Figure 2C) and m6A/ Ψ double modification were tested and found to second that LPS and unmethylated DNA (CpG ODN), be nonstimulatory, whereas…”
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Toll-like receptors and innate immunity
Medzhitov, R. (2001) · Nature Reviews Immunology · doi:10.1038/35100529 · Cited by 4,308
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis
Wang, T., Town, T., Alexopoulou, L., Anderson, J. F., Fikrig, E., & Flavell, R. A. (2004) · Nature Medicine · doi:10.1038/nm1140 · Cited by 1,142
mRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062
Self-citationHuman TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
Jurk, M., Heil, F., Vollmer, J., Schetter, C., Krieg, A. M., Wagner, H., Lipford, G., & Bauer, S. (2002) · Nature Immunology · doi:10.1038/ni0602-499 · Cited by 838
Subcellular Localization of Toll-Like Receptor 3 in Human Dendritic Cells
Matsumoto, M., Funami, K., Tanabe, M., Oshiumi, H., Shingai, M., Seto, Y., Yamamoto, A., & Seya, T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3154 · Cited by 723
Santini, S. M., Lapenta, C., Logozzi, M., Parlato, S., Spada, M., Pucchio, T. D., & Belardelli, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.10.1777 · Cited by 644
Cited by
Sorted by citations
Items 501–600 of 1,004
Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis
Haque, A. K. M. A., Dewerth, A., Antony, J. S., Riethmüller, J., Schweizer, G. R., Weinmann, P., Latifi, N., Yasar, H., Pedemonte, N., Sondo, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34960-0 · Cited by 80
Crowley, S. T., Fukushima, Y., Uchida, S., Kataoka, K., & Itaka, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.06.016 · Cited by 80
mRNA in cancer immunotherapy: beyond a source of antigen
Hoecke, L. V., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K. Y., Breckpot, K., & Lint, S. V. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01329-3 · Cited by 85
Post-transcriptional regulation of antiviral gene expression by N6-methyladenosine
McFadden, M. J., McIntyre, A. B. R., Mourelatos, H. A., Abell, N. S., Gokhale, N. S., Ipas, H., Xhemalçe, B., Mason, C. E., & Horner, S. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108798 · Cited by 80
Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics
Semple, S. C., Leone, R. D., Barbosa, C., Tam, Y. K., & Lin, P. J. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020398 · Cited by 80
Koenig, A., & Buskiewicz, I. A. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0073 · Cited by 78
Activation of Dendritic Cells by Toll-Like Receptors and C-Type Lectins
Diebold, S. S. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-71029-5_1 · Cited by 84
Chandola, U., Das, R., & Panda, B. (2014) · Briefings in Functional Genomics · doi:10.1093/bfgp/elu039 · Cited by 80
Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention
Kim, W., Sreih, A. G., & Bucala, R. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.07.046 · Cited by 80
Extracellular Ribonucleic Acids (RNA) Enter the Stage in Cardiovascular Disease
Zernecke, A., & Preissner, K. T. (2016) · Circulation Research · doi:10.1161/circresaha.115.307961 · Cited by 80
Transcript-activated collagen matrix as sustained mRNA delivery system for bone regeneration
Badieyan, Z. S., Berezhanskyy, T., Utzinger, M., Aneja, M. K., Emrich, D., Erben, R. G., Schüler, C., Altpeter, P., Ferizi, M., Hasenpusch, G., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.037 · Cited by 80
HIV mRNA Vaccines—Progress and Future Paths
Mu, Z., Haynes, B. F., & Cain, D. W. (2021) · Vaccines · doi:10.3390/vaccines9020134 · Cited by 84
Deep generative models design mRNA sequences with enhanced translational capacity and stability
Zhang, H., Liu, H., Xu, Y., Huang, H., Liu, Y., Wang, J., Qin, Y., Wang, H., Ma, L., Xun, Z., et al. (2025) · Science · doi:10.1126/science.adr8470 · Cited by 98
Regulatory molecules required for nucleotide‐sensing Toll‐like receptors
Saitoh, S.-I., & Miyake, K. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00729.x · Cited by 83
Maximizing the Translational Yield of mRNA Therapeutics by Minimizing 5′-UTRs
Trepotec, Z., Aneja, M. K., Geiger, J., Hasenpusch, G., Plank, C., & Rudolph, C. (2019) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0485 · Cited by 77
mRNA vaccines: the most recent clinical applications of synthetic mRNA
Kwon, S., Kwon, M., Im, S., Lee, K., & Lee, H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01381-7 · Cited by 85
Kennedy, E. M., Courtney, D., Tsai, K., & Cullen, B. R. (2017) · Journal of Virology · doi:10.1128/jvi.02263-16 · Cited by 84
Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy
Duan, L.-J., Wang, Q., Zhang, C., Yang, D.-X., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923647 · Cited by 83
Emerging delivery approaches for targeted pulmonary fibrosis treatment
Diwan, R., Bhatt, H., Beaven, E., & Nurunnabi, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115147 · Cited by 81
Nallagatla, S. R., Toroney, R., & Bevilacqua, P. C. (2008) · RNA Biology · doi:10.4161/rna.5.3.6839 · Cited by 79
All is not Toll: new pathways in DNA recognition
Wagner, H., & Bauer, S. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052191 · Cited by 77
Recent Progress in Chemically Modified siRNAs
Gaglione, M., & Messere, A. (2010) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955710791384036 · Cited by 76
Moradian, H., Roch, T., Anthofer, L., Lendlein, A., & Gossen, M. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.004 · Cited by 77
Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development
Schmidt, C., & Schnierle, B. S. (2023) · Pathogens · doi:10.3390/pathogens12010138 · Cited by 78
mRNA Cancer Vaccines: Construction and Boosting Strategies
Liu, X., Huang, P., Yang, R., & Deng, H. (2023) · ACS Nano · doi:10.1021/acsnano.3c05635 · Cited by 79
Advances in the design and development of SARS-CoV-2 vaccines
Peng, X., Cheng, J., Gong, H., Yuan, M.-D., Zhao, X., Li, Z., & Wei, D. (2021) · Military Medical Research · doi:10.1186/s40779-021-00360-1 · Cited by 84
Viral and Synthetic RNA Vector Technologies and Applications
Schott, J. W., Morgan, M., Galla, M., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.143 · Cited by 76
Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery
Żak, M. M., & Zangi, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101675 · Cited by 75
Potential Therapeutic Applications of Rna Cap Analogs
Ziemniak, M., Strenkowska, M., Kowalska, J., & Jemielity, J. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.96 · Cited by 76
Bacterial RNA is recognized by different sets of immunoreceptors
Eberle, F., Sirin, M., Binder, M., & Dalpke, A. H. (2009) · European Journal of Immunology · doi:10.1002/eji.200838978 · Cited by 76
Ballarín-González, B., Dagnæs‐Hansen, F., Fenton, R. A., Gao, S., Hein, S., Dong, M., Kjems, J., & Howard, K. A. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.2 · Cited by 76
Poleganov, M. A., Eminli, S., Beissert, T., Herz, S., Moon, J.-I., Goldmann, J., Beyer, A., Heck, R., Burkhart, I., Barea Roldan, D., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.045 · Cited by 77
Steinle, H., Behring, A., Schlensak, C., Wendel, H. P., & Avci‐Adali, M. (2016) · Stem Cells · doi:10.1002/stem.2402 · Cited by 78
siRNA therapeutics and its challenges: Recent advances in effective delivery for cancer therapy
Paul, A., Muralidharan, A., Biswas, A., Kamath, B. V., Joseph, A., & Alex, A. T. (2022) · OpenNano · doi:10.1016/j.onano.2022.100063 · Cited by 81
Spray dried lipid nanoparticle formulations enable intratracheal delivery of mRNA
Friis, K. P., Gracin, S., Oag, S., Leijon, A., Sand, E., Lindberg, B., Lázaro‐Ibáñez, E., Lindqvist, J., Whitehead, K. A., & Bak, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.031 · Cited by 79
N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation
Monroe, J. G., Eyler, D. E., Mitchell, L., Deb, I., Bojanowski, A., Srinivas, P., Dunham, C. M., Roy, B., Frank, A. T., & Koutmou, K. S. (2024) · Nature Communications · doi:10.1038/s41467-024-51301-0 · Cited by 83
Genetic modulation of TLR8 response following bacterial phagocytosis
Gantier, M. P., Irving, A. T., Kaparakis‐Liaskos, M., Xu, D., Evans, V. A., Cameron, P. U., Bourne, J. A., Ferrero, R. L., John, M., Behlke, M. A., et al. (2010) · Human Mutation · doi:10.1002/humu.21321 · Cited by 75
Beyond dsRNA: Toll-like receptor 3 signalling in RNA-induced immune responses
Tatematsu, M., Seya, T., & Matsumoto, M. (2014) · Biochemical Journal · doi:10.1042/bj20131492 · Cited by 77
Atherosclerosis and the Capillary Network; Pathophysiology and Potential Therapeutic Strategies
Ziegler, T., Rahman, F. A., Jurisch, V., & Kupatt, C. (2019) · Cells · doi:10.3390/cells9010050 · Cited by 80
Moradian, H., Roch, T., Lendlein, A., & Gossen, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60506-4 · Cited by 77
Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes
Veiga, N., Diesendruck, Y., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.002 · Cited by 78
Mehta, A., Michler, T., & Merkel, O. M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001650 · Cited by 76
mRNA therapeutics: New vaccination and beyond
Wei, H. Y., Zheng, L., & Wang, Z. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.02.022 · Cited by 77
Kim, S., Jeon, J. H., Kim, M., Lee, Y., Hwang, Y.-H., Park, M., Li, C. H., Lee, T., Lee, J.-A., Kim, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51411-9 · Cited by 78
Martin, D. A., & Elkon, K. B. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20052228 · Cited by 74
Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9
Bauer, S., Pigisch, S., Hangel, D., Kaufmann, A. M., & Hamm, S. (2007) · Immunobiology · doi:10.1016/j.imbio.2007.10.010 · Cited by 74
mRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 76
Double-stranded RNA reduction by chaotropic agents during in vitro transcription of messenger RNA
Piao, X., Yadav, V., Wang, E., Chang, W., Tau, L., Lindenmuth, B. E., & Wang, S. X. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.001 · Cited by 73
The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 72
tRNA therapeutics for genetic diseases
Coller, J., & Ignatova, Z. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00829-9 · Cited by 72
Linking vaccine adjuvant mechanisms of action to function
Ben‐Akiva, E., Chapman, A. P., Mao, T., & Irvine, D. J. (2025) · Science Immunology · doi:10.1126/sciimmunol.ado5937 · Cited by 83
The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients
Meng, Z., Yuan, Q., Zhao, J., Wang, B., Li, S., Offringa, R., Jin, X., & Wu, H. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.04.011 · Cited by 72
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 81
Vallazza, B., Petri, S., Poleganov, M. A., Eberle, F., Kuhn, A. N., & Şahin, U. (2015) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1288 · Cited by 74
Activation of Autoreactive B Cells by Endogenous TLR7 and TLR3 RNA Ligands
Green, N. M., Moody, K.-S., Debatis, M. E., & Marshak‐Rothstein, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.383000 · Cited by 72
Engineering Antiviral Vaccines
Zhou, X., Jiang, X., Qu, M., Aninwene, G. E., Jucaud, V., Moon, J. J., Gu, Z., Sun, W., & Khademhosseini, A. (2020) · ACS Nano · doi:10.1021/acsnano.0c06109 · Cited by 72
Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors
Ye, T., Li, F., Ma, G., & Wei, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113927 · Cited by 73
Lyu, Y., Wang, T., Huang, S., & Zhang, Z. (2023) · Journal of Innate Immunity · doi:10.1159/000533602 · Cited by 76
Pestiviruses: How to outmaneuver your hosts
Peterhans, E., & Schweizer, M. (2009) · Veterinary Microbiology · doi:10.1016/j.vetmic.2009.09.038 · Cited by 71
mRNA-based therapeutics–Advances and perspectives
Sergeeva, O. V., Koteliansky, V., & Zatsepin, T. S. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916070075 · Cited by 74
Schrom, E., Huber, M., Aneja, M., Dohmen, C., Emrich, D., Geiger, J., Hasenpusch, G., Herrmann-Janson, A., Kretzschmann, V., Mykhailyk, O., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.006 · Cited by 69
Messenger RNA (mRNA) nanoparticle tumour vaccination
Phua, K. K. L., Nair, S. K., & Leong, K. W. (2014) · Nanoscale · doi:10.1039/c4nr01346h · Cited by 70
Ge, Q., Dallas, A., Ilves, H., Shorenstein, J., Behlke, M. A., & Johnston, B. H. (2009) · RNA · doi:10.1261/rna.1901810 · Cited by 70
Recent advances in mRNA vaccine delivery
Tan, L., & Sun, X. (2018) · Nano Research · doi:10.1007/s12274-018-2091-z · Cited by 71
mRNA vaccines: The future of prevention of viral infections?
Rzymski, P., Szuster‐Ciesielska, A., Dzieciątkowski, T., Gwenzi, W., & Fal, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28572 · Cited by 75
ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy
Teng, X., Zhao, X., Dai, Y., Zhang, X., Zhang, Q., Wu, Y., Hu, D., & Li, J. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c06402 · Cited by 71
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 64
Factors, enablers and challenges for COVID-19 vaccine development
Excler, J., Saville, M. K., Privor-Dumm, L. A., Gilbert, S. E., Hotez, P. J., Thompson, D., Karim, S. S. A., & Kim, J. H. (2023) · BMJ Global Health · doi:10.1136/bmjgh-2023-011879 · Cited by 70
Xu, H., Kong, L., Cheng, J., Moussawi, K. A., Chen, X., Iqbal, A., Wing, P. A. C., Harris, J. M., Tsukuda, S., Buh, A. E., et al. (2024) · Nature Methods · doi:10.1038/s41592-024-02439-8 · Cited by 68
Bangel‐Ruland, N., Tomczak, K., Fernández, E. F., Leier, G., Leciejewski, B., Rudolph, C., Rosenecker, J., & Weber, W. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2748 · Cited by 67
Bioengineering of noncoding RNAs for research agents and therapeutics
Ho, P. Y., & Yu, A. (2016) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1324 · Cited by 68
Chen, S., Zaifman, J., Kulkarni, J. A., Zhigaltsev, I. V., Tam, Y. K., Ciufolini, M. A., Tam, Y. Y. C., & Cullis, P. R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.026 · Cited by 68
Precision RNA base editing with engineered and endogenous effectors
Pfeiffer, L. S., & Stafforst, T. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01927-0 · Cited by 68
RNA Therapeutics for the Cardiovascular System
Dzau, V. J., & Hodgkinson, C. P. (2024) · Circulation · doi:10.1161/circulationaha.123.067373 · Cited by 72
The fat mass and obesity-associated (FTO) gene: Obesity and beyond?
Hess, M. E., & Brüning, J. C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.01.017 · Cited by 71
Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells
Blanchet, M., Sinnathamby, V., Vaillant, A., & Labonté, P. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.02.009 · Cited by 67
Devoldere, J., Peynshaert, K., Dewitte, H., Vanhove, C., Groef, L. D., Moons, L., Özcan, S. Y., Dalkara, D., Smedt, S. C. D., & Remaut, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.042 · Cited by 70
Codon-optimization in gene therapy: promises, prospects and challenges
Paremskaia, A. I., Kogan, A. A., Murashkina, A., Naumova, D. A., Satish, A., Abramov, I. S., Feoktistova, S. G., Mityaeva, O. N., Deviatkin, A. A., & Volchkov, P. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1371596 · Cited by 66
Hameed, S. A., Paul, S., Dellosa, G. K. Y., Jaraquemada, D., & Bello, M. B. (2022) · npj Vaccines · doi:10.1038/s41541-022-00485-x · Cited by 65
Advanced delivery systems for peptide antibiotics
Cesaro, A., Lin, S., Pardi, N., & de la Fuente‐Núñez, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114733 · Cited by 67
Review of machine learning for lipid nanoparticle formulation and process development
Dorsey, P. J., Lau, C. L., Chang, T., Doerschuk, P. C., & D’Addio, S. M. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.09.015 · Cited by 74
RNA-Based Tools for Nuclear Reprogramming and Lineage-Conversion: Towards Clinical Applications
Bernal, J. A. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9494-8 · Cited by 65
The Epitranscriptome and Innate Immunity
O’Connell, M. A., Mannion, N., & Keegan, L. P. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005687 · Cited by 65
Nucleic Acid-Sensing TLRs as Modifiers of Autoimmunity
Deane, J. A., & Bolland, S. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6573 · Cited by 65
Prophylactic and therapeutic implications of toll-like receptor ligands
Hedayat, M., Takeda, K., & Rezaei, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.20214 · Cited by 76
Exploring the epitranscriptome by native RNA sequencing
Begik, O., Mattick, J. S., & Novoa, E. M. (2022) · RNA · doi:10.1261/rna.079404.122 · Cited by 65
RNA 5-Methylcytosine Analysis by Bisulfite Sequencing
Schaefer, M. (2015) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2015.03.007 · Cited by 64
Trendelenburg, G. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600609 · Cited by 64
Feng, Y., Chen, H., Cai, J., Zou, L., Yan, D., Xu, G., Li, D., & Chao, W. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.661835 · Cited by 64
Chien, K. R., Zangi, L., & Lui, K. O. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014035 · Cited by 64
Makkar, S. K. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1675209 · Cited by 72
Physicochemical characterization techniques for lipid based delivery systems for siRNA
Kapoor, M., Burgess, D. J., & Patil, S. D. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.09.032 · Cited by 64
Latest Development on RNA-Based Drugs and Vaccines
Lundstrom, K. H. (2018) · Future Science OA · doi:10.4155/fsoa-2017-0151 · Cited by 65
SARS-CoV-2 Subgenomic RNAs: Characterization, Utility, and Perspectives
Long, S. (2021) · Viruses · doi:10.3390/v13101923 · Cited by 67
The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
Föhse, K., Geckin, B., Zoodsma, M., Kılıç, G., Liu, Z., Röring, R. J., Overheul, G. J., van de Maat, J., Bulut, O. P., Hoogerwerf, J. J., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109762 · Cited by 64
Transfer RNA modifications and cellular thermotolerance
Ohira, T., & Suzuki, T. (2024) · Molecular Cell · doi:10.1016/j.molcel.2023.11.041 · Cited by 62
AKT kinases as therapeutic targets
Hassan, D., Menges, C. W., Testa, J. R., & Bellacosa, A. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03207-4 · Cited by 70
Small-Molecule TLR8 Antagonists via Structure-Based Rational Design
Hu, Z., Tanji, H., Jiang, S., Zhang, S., Koo, K., Chan, J. H., Sakaniwa, K., Ohto, U., Candia, A. F., Shimizu, T., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.07.004 · Cited by 62
Linares-Fernández, S., Moreno, J., Lambert, E., Mercier-Gouy, P., Vachez, L., Verrier, B., & Exposito, J.-Y. (2021) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2021.10.007 · Cited by 62
Metadata
- Authors
- Karikó, K., Buckstein, M., Ni, H., & Weissman, D.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Karikó, Katalin
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2005-08
- Volume
- 23
- Issue
- 2
- Pages
- 165-175
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2025980739
- Cited by
- 2,728
- References
- 35
- Citations by year
- 2026: 319 · 2025: 387 · 2024: 355 · 2023: 323 · 2022: 296 · 2021: 267 · 2020: 86 · 2019: 76 · 2018: 80 · 2017: 58 · 2016: 66 · 2015: 58 · 2014: 48 · 2013: 46 · 2012: 39
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (AI-50484, AI 060505, R01AI050484, R01AI060505)
- National Institute of Dental and Craniofacial Research (R01DE014825, DE 14825)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- Toll-like receptors, RNA recognition, nucleoside modification, TLR3, TLR7, TLR8, m5C, N6-methyladenosine, pseudouridine, dendritic cells, innate immunity, CpG methylation, mitochondrial RNA, bacterial RNA, RNA evolution, cytokine expression
- MeSH terms
- CD83 Antigen, Cell Line, Dendritic Cells, HLA-DR Antigens, Humans, Immunoglobulins, Membrane Glycoproteins, Nucleosides, Phosphatidylethanolamines, Receptors, Cell Surface, RNA, Signal Transduction, Biomarkers, Antigens, CD, Cytokines, Evolution, Molecular, Toll-Like Receptors, Toll-Like Receptor 3, Toll-Like Receptor 7, Toll-Like Receptor 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
